Patent ID: 7759472
Filing Date: 2010-07-20
Classification: A61K,A61P,C12N

Abstract:
1. A method for suppressing an ocular neovascular disorder in a patient in need thereof wherein the ocular disorder is ischemic retinopathy, iris neovascularization, intraocular neovascularization, age-related macular degeneration, corneal neovascularization, retinal neovascularization, choroidal neovascularization, diabetic retinal ischemia, or proliferative diabetic retinopathy, the method comprising administering to the patient: (i) a PDGF antagonist that is a pegylated aptamer whose sequence is CAGGCUACGN CGTAGAGCAU CANTGATCCU GT (SEQ ID NO:23) having 2′-fluoro-2′deoxyuridine at positions 6, 20 and 30, 2′-fluoro-2′deoxycytidine at positions 8, 21, 28, and 29, 2′-O-Methyl-2′-deoxyguanosine at positions 9, 15, 17, and 31, 2′-O-Methyl-2′-deoxyadenosine at position 22, “N” in positions 10 and 23 from a hexaethylene-glycol phosphoramidite, and an inverted orientation T at position 32; and (ii) a VEGF antagonist that is pegaptanib or a salt thereof, wherein the PDGF antagonist and the VEGF antagonist are administered simultaneously or within 90 days of each other, and wherein the PDGF antagonist and the VEGF antagonist are administered in an amount effective to suppress the ocular neovascular disorder in the patient.